Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 May 23;18(1):230.
doi: 10.1186/s13063-017-1966-8.

Fibrates for the treatment of cholestatic itch (FITCH): study protocol for a randomized controlled trial

Ruth Bolier  1 , Elsemieke S de Vries  2 , Albert Parés  3 , Jeltje Helder  2 , E Marleen Kemper  4 , Koos Zwinderman  5 , Ronald P Oude Elferink  2 , Ulrich Beuers  2 ; Netherlands Association for the Study of the Liver (NASL) Cholestatic Liver Diseases Study Group
Collaborators, Affiliations
Randomized Controlled Trial

Fibrates for the treatment of cholestatic itch (FITCH): study protocol for a randomized controlled trial

Ruth Bolier et al. Trials. .

Abstract

Background: Pruritus (itch) is a frequent, burdensome and difficult-to-treat symptom in patients with cholestasis. Fibrates are currently under investigation for the treatment of primary biliary cholangitis in patients with a suboptimal response to ursodeoxycholic acid. Moreover, there is empirical evidence for a possible antipruritic effect. We aim to prove this in a randomized controlled trial, including patients with cholestatic liver diseases other than primary biliary cholangitis that are accompanied by pruritus.

Methods: A multicenter investigator-initiated, double-blind, randomized placebo-controlled trial to evaluate the effect of bezafibrate on cholestatic pruritus in 84 adult patients with primary biliary cholangitis or primary/secondary sclerosing cholangitis. Primary outcome is the proportion of patients with a reduction of itch intensity of 50% or more (measured on a Visual Analog Scale) after 21 days of treatment with bezafibrate 400 mg qid or placebo. Secondary outcomes include the effect of bezafibrate on a five-dimensional itch score, liver disease-specific quality of life, serum liver tests and autotaxin activity. Safety will be evaluated through serum parameters for kidney function and rhabdomyolysis as well as precise recording of (serious) adverse events. We provide a schematic overview of the study protocol and describe the methods used to recruit and randomize patients, collect and handle data and perform statistical analyses.

Discussion: Given its favorable safety profile and anticholestatic properties, bezafibrate may become the new first-line treatment option for treating cholestatic pruritus.

Trial registration: Netherlands Trial Register, ID: NCT02701166 . Registered on 2 March 2016; Netherlands Trial Register, ID: NTR5436 . Registered on 3 August 2015.

Keywords: Bezafibrate; Itch; Primary biliary cholangitis; Primary sclerosing cholangitis; Pruritus; Secondary sclerosing cholangitis.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) figure: schedule of enrollment, interventions and assessments. 5D five-dimensional, LDSI Liver Disease Symptom Index, VAS Visual Analog Scale
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, et al. Changing nomenclature for PBC: from ‘cirrhosis’ to ‘cholangitis’. Hepatology. 2015;62:1620–2. doi: 10.1002/hep.28140. - DOI - PubMed
    1. Beuers U, Kremer AE, Bolier AR, Oude Elferink RPJ. Pruritus in cholestasis: facts and fiction. Hepatology. 2014;60:399–407. doi: 10.1002/hep.26909. - DOI - PubMed
    1. Kuiper EM, Hansen BE, Metselaar HJ, de Man RA, Haagsma EB, van Hoek B, et al. Trends in liver transplantation for primary biliary cirrhosis in the Netherlands 1988–2008. BMC Gastroenterol. 2010;10:144. doi: 10.1186/1471-230X-10-144. - DOI - PMC - PubMed
    1. Beuers U, Boberg K, Chapman R, Chazouillères OIP, Jones D, Lammert F, et al. EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatology. 2009;51:237–67. doi: 10.1016/j.jhep.2009.09.018. - DOI - PubMed
    1. Miyaguchi S, Ebinuma H, Imaeda H, Nitta Y, Watanabe T, Saito H, et al. A novel treatment for refractory primary biliary cirrhosis? Hepatogastroenterology. 2000;47:1518–21. - PubMed

Publication types

Associated data